BACKGROUND:Calcitriol deficit has been described in patients with acute lymphoblast leukemia (ALL). The aim of this randomized case-control trial is to investigate the effectiveness of calcitriol administration during the first year of treatment to protect bone mass. Sixteen children recently diagnosed with ALL, aged 1.7 to 11.5 years, average 5.5, completed the study. Anthropometrical measurements, food intake record, physical activity, and bone pain were registered. Dual energy x-ray absorptiometry was performed at the completion of remission induction chemotherapy (after 1 mo) to measure bone mineral density (BMD) at hip, lumbar spine and whole body, and total bone mineral content and 1 year after. Half of them were randomly assigned to receive calcitriol during 1 year. STATISTICAL: Kruskal-Wallis, Wilcoxon, Mann-Whitney, and Spearman. RESULTS: Both groups had similar anthropometric measurements and bone densitometric variables increments. Spine BMD significantly increased in calcitriol supplemented children with lower baseline BMD (r=-0.78 and P<0.05). CONCLUSIONS: One-year calcitriol administered to recently diagnosed ALL children did not show impact on bone mass. Greater increment in lumbar spine bone mass was observed in patients who received calcitriol and had lower baseline BMD.
RCT Entities:
BACKGROUND:Calcitriol deficit has been described in patients with acute lymphoblast leukemia (ALL). The aim of this randomized case-control trial is to investigate the effectiveness of calcitriol administration during the first year of treatment to protect bone mass. Sixteen children recently diagnosed with ALL, aged 1.7 to 11.5 years, average 5.5, completed the study. Anthropometrical measurements, food intake record, physical activity, and bone pain were registered. Dual energy x-ray absorptiometry was performed at the completion of remission induction chemotherapy (after 1 mo) to measure bone mineral density (BMD) at hip, lumbar spine and whole body, and total bone mineral content and 1 year after. Half of them were randomly assigned to receive calcitriol during 1 year. STATISTICAL: Kruskal-Wallis, Wilcoxon, Mann-Whitney, and Spearman. RESULTS: Both groups had similar anthropometric measurements and bone densitometric variables increments. Spine BMD significantly increased in calcitriol supplemented children with lower baseline BMD (r=-0.78 and P<0.05). CONCLUSIONS: One-year calcitriol administered to recently diagnosed ALL children did not show impact on bone mass. Greater increment in lumbar spine bone mass was observed in patients who received calcitriol and had lower baseline BMD.
Authors: Jill H Simmons; Eric J Chow; Elizabeth Koehler; Adam Esbenshade; Lesley-Ann Smith; Jean Sanders; Debra Friedman Journal: Pediatr Blood Cancer Date: 2010-12-22 Impact factor: 3.167
Authors: S C Kaste; A Qi; K Smith; H Surprise; E Lovorn; J Boyett; R J Ferry; M V Relling; S A Shurtleff; C H Pui; L Carbone; M M Hudson; K K Ness Journal: Pediatr Blood Cancer Date: 2014-01-07 Impact factor: 3.167
Authors: L J Peppone; S Hebl; J Q Purnell; M E Reid; R N Rosier; K M Mustian; O G Palesh; A J Huston; M N Ling; G R Morrow Journal: Osteoporos Int Date: 2009-12-04 Impact factor: 4.507
Authors: Paula Aristizabal; Michael Sherer; Bianca P Perdomo; Esteban Castelao; Courtney D Thornburg; James Proudfoot; Elizabeth Jacobs; Ron S Newfield; Peter Zage; William Roberts; Maria Elena Martinez Journal: Pediatr Hematol Oncol Date: 2020-03-10 Impact factor: 1.969
Authors: Andrea L Radossi; Katherine Taromina; Stacey Marjerrison; Caroline J Diorio; Raquel Similio; Festus Njuguna; Glenn M Afungchwi; Elena J Ladas Journal: Support Care Cancer Date: 2017-10-13 Impact factor: 3.603
Authors: Eliza Turlej; Tomasz Marek Goszczyński; Marek Drab; Beata Orzechowska; Magdalena Maciejewska; Joanna Banach; Joanna Wietrzyk Journal: J Clin Med Date: 2022-04-15 Impact factor: 4.964
Authors: Jenneke E van Atteveld; Iris E Verhagen; Marry M van den Heuvel-Eibrink; Hanneke M van Santen; Inge M van der Sluis; Natascia Di Iorgi; Jill H Simmons; Leanne M Ward; Sebastian J C M M Neggers Journal: Cancer Med Date: 2021-06-08 Impact factor: 4.452